Last reviewed · How we verify
olmesartan medoxomil and a CCB
olmesartan medoxomil and a CCB is a Angiotensin II receptor blocker / Calcium channel blocker combination Small molecule drug developed by Daiichi Sankyo Co., Ltd.. It is currently FDA-approved for Hypertension.
This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through dual vasodilation and reduced vascular resistance.
This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through dual vasodilation and reduced vascular resistance. Used for Hypertension.
At a glance
| Generic name | olmesartan medoxomil and a CCB |
|---|---|
| Sponsor | Daiichi Sankyo Co., Ltd. |
| Drug class | Angiotensin II receptor blocker / Calcium channel blocker combination |
| Target | AT1 receptor; L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. The calcium channel blocker (CCB) component inhibits calcium influx into vascular smooth muscle cells, causing additional vasodilation. Together, these complementary mechanisms provide synergistic blood pressure reduction.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Peripheral edema
- Hyperkalemia
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension (PHASE4)
- Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension (PHASE4)
- Lowering Blood Pressure in Primary Care in Vienna (PHASE4)
- An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- olmesartan medoxomil and a CCB CI brief — competitive landscape report
- olmesartan medoxomil and a CCB updates RSS · CI watch RSS
- Daiichi Sankyo Co., Ltd. portfolio CI
Frequently asked questions about olmesartan medoxomil and a CCB
What is olmesartan medoxomil and a CCB?
How does olmesartan medoxomil and a CCB work?
What is olmesartan medoxomil and a CCB used for?
Who makes olmesartan medoxomil and a CCB?
What drug class is olmesartan medoxomil and a CCB in?
What development phase is olmesartan medoxomil and a CCB in?
What are the side effects of olmesartan medoxomil and a CCB?
What does olmesartan medoxomil and a CCB target?
Related
- Drug class: All Angiotensin II receptor blocker / Calcium channel blocker combination drugs
- Target: All drugs targeting AT1 receptor; L-type voltage-gated calcium channel
- Manufacturer: Daiichi Sankyo Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Compare: olmesartan medoxomil and a CCB vs similar drugs
- Pricing: olmesartan medoxomil and a CCB cost, discount & access